Valuation: Outlook Therapeutics, Inc.

Market Cap 14Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 144.98Cr 56Cr 709.6Cr 54Cr 53Cr 2.28TCr P/E 2026 *
-1.02x
P/E 2027 * -2.74x
Enterprise Value 14Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 144.98Cr 56Cr 709.6Cr 54Cr 53Cr 2.28TCr EV / Sales 2026 *
211x
EV / Sales 2027 * 3.28x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week-4.12%
Current month+3.84%
1 month-7.03%
3 months-58.06%
6 months+196.86%
Current year-62.31%
1 week 0.53
Extreme 0.5314
0.64
1 month 0.53
Extreme 0.5314
0.74
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
46.2
10 years 0.16
Extreme 0.1611
704
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Director of Finance/CFO 59 01/09/2026
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Director/Board Member 50 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Chief Financial Officer

5,00,000 0.3122%
14/08/26 Buy

Chief Executive Officer

2,02,020 0.0832%
14/08/26 Buy

Chief Executive Officer

3,03,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-4.12%-45.37%-86.96% 14Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-0.37%-3.88%+19.75%+78.35% 5.74TCr
+1.63%+0.98%+3.83%+38.21% 4.76TCr
+0.50%+2.94%+345.86%+722.17% 4.43TCr
+3.05%-1.80%+29.79%+34.51% 4.25TCr
+1.00%-1.46%+4.97%+111.90% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.56%+4.53%+31.34%+26.92% 2.85TCr
+0.76%-1.45%-7.15%-11.12% 2.43TCr
Average +1.19%-1.26%+44.17%+106.22% 3.91TCr
Weighted average by Cap. +1.52%-0.84%+58.27%+136.86%

Financials

2026 *2027 *
Net sales 7L 6L 6L 5L 10L 6.57Cr 10L 68.56L 26.67L 3.36Cr 25.63L 25.07L 11Cr 4.41Cr 3.93Cr 3.66Cr 3.33Cr 6.28Cr 424.43Cr 6.32Cr 44Cr 17Cr 216.62Cr 17Cr 16Cr 696.3Cr
Net income -6.51Cr -5.81Cr -5.41Cr -4.92Cr -9.27Cr -626.96Cr -9.34Cr -65Cr -25Cr -319.99Cr -24Cr -24Cr -1.03TCr -4.44Cr -3.96Cr -3.69Cr -3.36Cr -6.33Cr -427.92Cr -6.38Cr -45Cr -17Cr -218.41Cr -17Cr -16Cr -702.03Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
06/26/06 $0.5955 +0.42% 45,25,666
02/26/02 $0.5930 +3.13% 56,19,583
01/26/01 $0.5750 +0.26% 70,68,830
30/26/30 $0.5735 -8.34% 90,11,677
29/26/29 $0.6257 +0.74% 45,83,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.5930USD
Average target price
5.025USD
Spread / Average Target
+747.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock